{"groups":[{"description":"Patients undergo pelvic EBRT or IMRT 5 days per week for 5 weeks (25 fractions) with a 3-day boost in week 6, and 1 or 2 applications of LDR brachytherapy in week 6 or 5 fractions of HDR brachytherapy at week 4 or 5. Patients also receive triapine IV over 120 minutes on day 1 and 100mg PO on days 2-5, 8-12, 15-19, 22-26, and 29-33 within 90 minutes after pelvic irradiation, and cisplatin IV over 60-120 minutes once weekly for 5 weeks (days 2, 9, 16, 23, and 30). Treatment continues in the absence of disease progression or unacceptable toxicity. Patients may receive a 6th cycle of cisplatin IV during the parametrial boost or any make-up radiation treatment in a sixth week of external beam radiotherapy. Patients undergo the collection of blood samples on study and undergo MRI and FDG-PET/CT during follow-up.\n\nBiospecimen Collection: Undergo collection of blood samples\n\nBrachytherapy: Undergo LDR brachytherapy\n\nCisplatin: Given IV\n\nComputed Tomography: Undergo FDG-PET/CT\n\nExternal Beam Radiation Therapy: Undergo pelvic EBRT\n\nFludeoxyglucose F-18: Undergo FDG-PET/CT\n\nHigh-Dose Rate Brachytherapy: Undergo HDR brachytherapy\n\nIntensity-Modulated Radiation Therapy: Undergo IMRT\n\nMagnetic Resonance Imaging: Undergo MRI\n\nPharmacological Study: Correlative studies\n\nPositron Emission Tomography: Undergo FDG-PET/CT\n\nTriapine: Given IV and PO","id":"FG000","title":"100 mg PO Triapine + Chemoradiation"},{"description":"Patients undergo pelvic EBRT or IMRT 5 days per week for 5 weeks (25 fractions) with a 3-day boost in week 6, and 1 or 2 applications of LDR brachytherapy in week 6 or 5 fractions of HDR brachytherapy at week 4 or 5. Patients also receive triapine IV over 120 minutes on day 1 and 100mg PO on days 2-5, 8-12, 15-19, 22-26, and 29-33 within 90 minutes after pelvic irradiation, and cisplatin IV over 60-120 minutes once weekly for 5 weeks (days 2, 9, 16, 23, and 30). Treatment continues in the absence of disease progression or unacceptable toxicity. Patients may receive a 6th cycle of cisplatin IV during the parametrial boost or any make-up radiation treatment in a sixth week of external beam radiotherapy. Patients undergo the collection of blood samples on study and undergo MRI and FDG-PET/CT during follow-up.\n\nBiospecimen Collection: Undergo collection of blood samples\n\nBrachytherapy: Undergo LDR brachytherapy\n\nCisplatin: Given IV\n\nComputed Tomography: Undergo FDG-PET/CT\n\nExternal Beam Radiation Therapy: Undergo pelvic EBRT\n\nFludeoxyglucose F-18: Undergo FDG-PET/CT\n\nHigh-Dose Rate Brachytherapy: Undergo HDR brachytherapy\n\nIntensity-Modulated Radiation Therapy: Undergo IMRT\n\nMagnetic Resonance Imaging: Undergo MRI\n\nPharmacological Study: Correlative studies\n\nPositron Emission Tomography: Undergo FDG-PET/CT\n\nTriapine: Given IV and PO","id":"FG001","title":"150 mg PO Triapine + Chemoradiation"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Cohort 1 / Dose Level 1"},{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"4"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"4"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Cohort 2 / Dose Level 2"},{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Cohort 3 / Dose Level 1"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Did not complete treatment regimen"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"0"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Expansion Cohort"}]}